Gypenosides pre‐treatment protects the brain against cerebral ischemia and increases neural stem cells/progenitors in the subventricular zone. Issue 33 (12th December 2013)

• Record Type: Journal Article
• Authors: Wang, Xiao‐Jing; Sun, Tao; Kong, Liang; Shang, Zhen‐Hua; Yang, Kun‐Qi; Zhang, Qing‐Yu; Jing, Fang‐Miao; Dong, Lun; Xu, Xu‐Feng; Liu, Jia‐xin; Xin, Hua; Chen, Zhe‐Yu
• Is Part Of: International journal of developmental neuroscience. Issue 33(2014:Apr.)
• Page Start: 49
• Page End: 56
• Publication Date: 2013-12-12
• Subjects: Subventricular zone -- Neurogenesis -- Stroke -- Cell proliferation -- Gypenosides; Developmental neurobiology -- Periodicals; Neurology -- Periodicals; Neurologie du développement -- Périodiques; Developmental neurobiology; Periodicals; 612.8
• DOI: 10.1016/j.ijdevneu.2013.12.001
• Languages: English
• ISSNs: 0736-5748

Abstract

Abstract: Gypenosides (GPs) have been reported to have neuroprotective effects in addition to other bioactivities. The protective activity of GPs during stroke and their effects on neural stem cells (NSCs) in the ischemic brain have not been fully elucidated. Here, we test the effects of GPs during stroke and on the NSCs within the subventricular zone (SVZ) of middle cerebral artery occlusion (MCAO) rats. Our results show that pre‐treatment with GPs can reduce infarct volume and improve motor function following MCAO. Pre‐treatment with GPs significantly increased the number of BrdU‐positive cells in the ipsilateral and contralateral SVZ of MCAO rats. The proliferating cells in both sides of the SVZ were glial fibrillary acidic protein (GFAP)/nestin‐positive type B cells and doublecortin (DCX)/nestin‐positive type A cells. Our data indicate that GPs have neuroprotective effects during stroke which might be mediated through the enhancement of neurogenesis within the SVZ. These findings provide new evidence for a potential therapy involving GPs for the treatment of stroke.